Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M
Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Clin Cancer Res. 2000 Jan;6(1):96-101.
The integrin family plays a major role in complex biological events such as differentiation, development, wound healing, and the altered adhesive and invasive properties of tumor cells. Integrin (alpha5beta1 is a classical fibronectin receptor, and it has been known as a tumor suppressor gene because tumor cells overexpressing alpha5beta1 are less tumorigenic than their parent cells. However, this finding conflicts with some recent data that suggests that the emergence of alpha5beta1 expression correlates with the tumor progression. We, therefore, investigated the expression of alpha5beta1 integrin in 20 lung cancer cell lines by flow cytometric analysis and in 88 node-negative non-small cell lung cancers (NSCLCs) by RT-PCR and immunohistochemical assays to determine the significance of this prognostic factor. In the 20 lung cancer cell lines, 8 (40.0%) cell lines strongly expressed integrin alpha5, 3 (15.0%) cell lines had moderate or weak alpha5 expression, and the remaining 9 (45.0%) cell lines expressed no integrin alpha5. In the 88 node-negative NSCLC patients, 44 samples (50.0%) were evaluated as having integrin alpha5 overexpression, and the integrin alpha5 expression was significantly associated with the status of differentiation and the age of the patients (P = 0.0379 and 0.0312, respectively). In the node-negative patients, the overall survival rate for patients with integrin alpha5 overexpressed tumors was significantly worse than for those individuals whose tumors had normal integrin alpha5 expression (P = 0.016).
整合素家族在复杂的生物学事件中发挥着重要作用,如分化、发育、伤口愈合以及肿瘤细胞黏附性和侵袭性的改变。整合素(α5β1)是一种经典的纤连蛋白受体,由于过表达α5β1的肿瘤细胞比其亲本细胞的致瘤性更低,它一直被视为一种肿瘤抑制基因。然而,这一发现与最近的一些数据相矛盾,这些数据表明α5β1表达的出现与肿瘤进展相关。因此,我们通过流式细胞术分析研究了20种肺癌细胞系中α5β1整合素的表达,并通过逆转录聚合酶链反应(RT-PCR)和免疫组织化学检测研究了88例淋巴结阴性非小细胞肺癌(NSCLC)中α5β1整合素的表达,以确定这一预后因素的意义。在20种肺癌细胞系中,8种(40.0%)细胞系强烈表达整合素α5,3种(15.0%)细胞系α5表达中等或较弱,其余9种(45.0%)细胞系不表达整合素α5。在88例淋巴结阴性NSCLC患者中,44份样本(50.0%)被评估为整合素α5过表达,整合素α5表达与患者的分化状态和年龄显著相关(P分别为0.0379和0.0312)。在淋巴结阴性患者中,整合素α5过表达肿瘤患者的总生存率明显低于肿瘤整合素α5表达正常的患者(P = 0.016)。